Selected stock price target news of the day - December 29th, 2023

By: Matthew Otto


Boston Scientific Launches AVANT GUARD Clinical Trial for FARAPULSE PFA System

Boston Scientific has launched the AVANT GUARD clinical trial, an initiative to assess the FARAPULSE Pulsed Field Ablation System as a primary treatment for persistent atrial fibrillation. Unlike conventional approaches, the FARAPULSE System employs non-thermal electric fields to selectively ablate heart tissue. The trial aims to compare the outcomes of this innovative treatment with the commonly prescribed anti-arrhythmic drug therapy for patients with persistent atrial fibrillation. Over 40,000 patients already treated, the FARAPULSE System demonstrates a safety and effectiveness profile.

According to Cleveland Clinic at least 2.7 million Americans live with atrial fibrillation. Researchers believe an estimated 70% of those cases are persistent or long-standing persistent Afib.

The randomized trial, enrolling over 500 patients globally, will evaluate the FARAPULSE System against anti-arrhythmic drug treatment over a three-year period. The outcomes will include device or procedure-related adverse events, rates of freedom from atrial fibrillation, atrial flutter, or atrial tachycardia, and the measurement of atrial fibrillation burden.


Analysts Bullish: Reiterate Ratings and Price Targets

  • BTIG analyst Marie Thibault reiterated a Buy rating and a $64 price target.
  • Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and a $62 price target.


Which Analyst has the best track record to show on BSX?

Analyst Vijay Kumar (EVERCORE) currently has the highest performing score on BSX with 6/7 (85.71%) price target fulfillment ratio. His price targets carry an average of $6.97 (13.14%) potential upside. Boston Scientific stock price reaches these price targets on average within 111 days. 




Daily stock Analysts Top Price Moves Snapshot